Brad Briggs is the Editorial Director of StreetAuthority. A veteran of the financial publishing industry, Brad manages the team of writers and editors responsible for our premium newsletters, free newsletters, and website. He formerly co-wrote our Maximum Profit premium newsletter and manages our premium subscribers-only newsletter, StreetAuthority Insider.
Brad bought his first stock in high school and has been hooked ever since. After graduating early from college, success in the market enabled him to pay off his student loans and buy his first house. And although he has experience in everything from momentum investing to options, one of his proudest investing accomplishments has been buying and holding on to Apple since 2014.
Brad believes that successful investing doesn't have to be complicated and that anyone can achieve financial independence regardless of background. As Editorial Director, Brad makes it his mission to demystify the world of investing for a wide audience. His writing has been featured in outlets like Yahoo Finance, Nasdaq.com, and MSN Money, among others.
An experienced powerlifter, Brad spends his time renovating and working on his property in Texas and tending to cattle when not following the market.
Analyst Articles
When the financial meltdown began with the collapse of Lehman Brothers, the talking heads on financial news channels pronounced the death of “buy-and-hold” investing. It had become unfashionable. No one was willing to defend the idea of buying a stock and holding on to it for years. I don’t know… Read More
China has had an impressive run. Its GDP has grown at double-digit rates while holders of Chinese stocks have earned triple-digit returns. While everyone else is talking about China, savvy investors should be asking where the next big growth story is. The investment company… Read More
The U.S. isn’t the only country struggling to reform its health-care system. China has a big problem on its hands: 1.3 billion people and a system that has been ignored for decades. The World Health Organization recently ranked China’s health care 144th out of 190 countries. The country recently said… Read More
Benjamin Graham, the father of value investing, once described his strategy as “buying dollars for 50 cents.” He would have loved this market. Graham had several tricks to determine whether a company was undervalued. One of them was assessing its book value, a figure… Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings season, while the S&P is up +10% for the year. The market couldn’t have made it to this point without a few stocks seeing substantial gains. Here are three stocks that have posted triple-digit gains this year. After analyzing how they did it, I’ll tell you three more companies that will follow suit. OshKosh (NYSE: OSK) YTD Gain: +191.5% Industrial equipment maker OshKosh faced major headwinds due to the economic downturn,… Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings season, while the S&P is up +10% for the year. The market couldn’t have made it to this point without a few stocks seeing substantial gains. Here are three stocks that have posted triple-digit gains this year. After analyzing how they did it, I’ll tell you three more companies that will follow suit. OshKosh (NYSE: OSK) YTD Gain: +191.5% Industrial equipment maker OshKosh faced major headwinds due to the economic downturn, and its shares sank as low as $4.95 in March. But just when things seemed to be at their worst, OSK posted strong growth, and the shares began to climb. The catalyst was a $1.05 billion contract to build military vehicles for use in Afghanistan that protect against roadside bombs. The contract, initially for 2,000 vehicles, could lead to as many as 10,000 vehicles and $4 billion to $5 billion in revenue. The shares are now trading near $27. How it Got There: A major catalyst thanks to Uncle Sam. General Cable (NYSE: BGC)… Read More
The largest savings and loan in the United States said second-quarter earnings were up 16% from last year. Net income rose to $127.9 million, or 26 cents a share, compared with $110.7 million, or 22 cents a… Read More
Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
Healthcare giant Johnson & Johnson (NYSE: JNJ) said this morning that second-quarter earnings amounted to $1.15 a share. The results, a -4.7% decline from a year ago, beat expectations, despite challenges facing the company’s pharmaceutical unit and a stronger dollar. The company said… Read More
A key measure of wholesale prices rose in June at nearly twice the increase economists had forecast. It was the sharpest rise for the index since November 2007. The Producer Price Index, which tracks how much it costs for manufacturers to make things,… Read More
The first half of 2009 has been nothing short of volatile for Wall Street. Between corporate bailouts, bankruptcies and unprecedented government spending, the news has been full of surprises. The assorted high-profile shenanigans of GM, AIG and others deserve their rightful place in the “Hall of Shame,” but there has… Read More
